To treat or not to treat? A meta-analysis of the use of cholinesterase inhibitors in mild cognitive impairment for delaying progression to Alzheimer’s disease
- 592 Downloads
Individual randomized clinical trials (RCTs) with cholinesterase inhibitors (ChEIs) aiming to delay the progression from mild cognitive impairment (MCI) to Alzheimer’s disease (AD) have not found significant benefit of their use for this purpose. The objective of this study is to meta-analyze the RCTs conducted with ChEIs in order to assess whether pooled analysis could show the benefit of these drugs in delaying the progression from MCI to AD.
We searched for references of published and unpublished studies on electronic databases (Medline, Embase, Web of Science, and Clinical Trial Database Registry, particularly the Clinicaltrials.gov—http://www.clinicaltrials.gov). We retrieved 173 references, which yielded three references for data extraction. A total of 3.574 subjects from four RCTs were included in the meta-analysis. Among 1,784 subjects allocated in the ChEI-treatment group, 275 (15.4%) progressed to AD/dementia, as opposed to 366 (20.4%) out of 1,790 subjects in the placebo group. The relative risk (RR) for progression to AD/dementia in the ChEI-treated group was 0.75 [CI95% 0.66–0.87], z = −3.89, P < 0.001. The patients on the ChEI group had a significantly higher all-cause dropout risk than the patients on the placebo group (RR = 1.36 CI95% [1.24–1.49]; z = 6.59, P < 0.001). The RR for serious adverse events (SAE) in the ChEI-treated group showed no significantly statistical difference from the placebo group (RR = 0.95 [CI95% 0.83–1.09], z = −0.72, P = 0.47). The subjects in the ChEI-treated group had a marginally, non-significant, higher risk of death due to any cause than those in the placebo-treated group (RR = 1.04, CI95% 0.63–1.70, z = 0.16, P = 0.86).
The long-term use of ChEIs in subjects with MCI may attenuate the risk of progression to AD/dementia. This finding may have a significant impact on public health and pharmaco-economic policies.
Keywordsmild cognitive impairment treatment disease-modifying therapies Alzheimer’s disease progression
Conflict of interest
Dr. Gattaz has received research support and speakership honoraria from AstraZeneca, Bristol Myers-Squibb, Eli Lilly, and Janssen-Cilag.
- 1.[No author listed] (2004) Efficacy and safety of rivastigmine in patients with mild cognitive impairment. NCT00134953. Available on-line on http://www.clinicaltrials.gov/ct2/show/NCT00134953. Accessed 27 Oct 2008
- 2.[No author’s listed]. (2007) A randomized double blind parallel, placebo-controlled trial to examine the efficacy of oral donepezil (5 mg qd for 6 weeks) after single dose and steady state therapy (2 and 6 weeks) in subjects with mild cognitive impairment. NCT00483028. Available on-line on http://clinicaltrials.gov/ct2/show/NCT00483028. Accessed 27 Oct 2008
- 3.[No authors listed] (2004) Cognitive enhancers explored with PET imaging. NCT 00042172. Available on-line http://clinicaltrials.gov/ct2/show/NCT00042172. Accessed 27 Oct 2008
- 5.Anita M (2007) A one-year, multicenter, randomized, double-blind, placebo controlled evaluation of the efficacy and safety of donepezil hydrochloride in subjects with mild cognitive impairment. NCT00293176. Available on line http://clinicaltrials.gov/ct2/show/NCT00293176. Accessed 27 Oct 2008
- 12.Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro OJ, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P (2007) Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6:734–746PubMedCrossRefGoogle Scholar
- 14.Feldman HH, Ferris S, Winblad B, Sfikas N, Mancione L, He Y, Tekin S, Burns A, Cummings J, del Ser T, Inzitari D, Orgogozo JM, Sauer H, Scheltens P, Scarpini E, Herrmann N, Farlow M, Potkin S, Charles HC, Fox NC, Lane R (2007) Effect of rivastigmine on delay to diagnosis of Alzheimer’s disease from mild cognitive impairment: the InDDEx study. Lancet Neurol 6:501–512PubMedCrossRefGoogle Scholar
- 25.López-Pousa S, Turon-Estrada A, Garre-Olmo J, Pericot-Nierga I, Lozano-Gallego M, Vilalta-Franch M, Hernández-Ferràndiz M, Morante-Muñoz V, Isern-Vila A, Gelada-Batlle E, Majó-Llopart J (2005) Differential efficacy of treatment with cholinesterase inhibitors in patients with mild and moderate Alzheimer’s disease over a 6-month period. Dement Geriatr Cogn Disord 19:189–195PubMedCrossRefGoogle Scholar
- 27.Mendes CT, Mury FB, de Sá Moreira E, Alberto FL, Forlenza OV, Dias-Neto E, Gattaz WF (2008) Lithium reduces Gsk3b mRNA levels: implications for Alzheimer’s disease. Eur Arch Psychiatry Clin Neurosci [Epub ahead of print]Google Scholar
- 28.National Institute for Clinical Excellence (NICE) (2004) Management of depression in primary and secondary care. The British Psychological Society and Gaskel. LeicesterGoogle Scholar
- 33.Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ, Alzheimer’s Disease Cooperative Study Group (2005) Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 352:2379–2388PubMedCrossRefGoogle Scholar
- 47.Wilkinson DG, Passmore AP, Bullock R, Hopker SW, Smith R, Potocnik FC, Maud CM, Engelbrecht I, Hock C, Ieni JR, Bahra RS (2002) A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer’s disease. Int J Clin Pract 56:441–446PubMedGoogle Scholar
- 50.Wolf BA, Wertkin AM, Jolly YC, Yasuda RP, Wolfe BB, Konrad RJ, Manning D, Ravi S, Williamson JR, Lee VM (1995) Muscarinic regulation of Alzheimer’s disease amyloid precursor protein secretion and amyloid beta-protein production in human neuronal NT2N cells. J Biol Chem 270:4916–4922PubMedCrossRefGoogle Scholar